期刊文献+

左旋氨氯地平与依达拉奉联合治疗脑梗死合并高血压临床效果观察 被引量:3

下载PDF
导出
摘要 目的:观察左旋氨氯地平与依达拉奉联合治疗脑梗死合并高血压临床效果。方法:抽取上蔡县人民医院2015年3月~2016年6月收治的80例脑梗死合并高血压患者,根据治疗方法不同分为两组,各40例。对照组采用依达拉奉治疗,研究组采用左旋氨氯地平联合依达拉奉治疗,两组均持续治疗20d。统计两组临床疗效、不良反应发生率及治疗前后神经功能评分。结果:两组神经功能评分比较,差异无统计学意义(P>0.05),治疗后研究组神经功能评分高于对照组,差异有统计学意义(P<0.05);研究组治疗总有效率为95.00%,对照组为80.00%,两组对比差异有统计学意义(P<0.05);研究组不良反应总发生率为12.50%,对照组为10.00%,两组对比差异无统计学意义(P>0.05)。结论:采用左旋氨氯地平联合依达拉奉治疗高血压合并脑梗死效果显著,可明显改善临床症状,提高治疗效果,安全性较高。
作者 马兆利
出处 《北方药学》 2017年第5期107-108,共2页 Journal of North Pharmacy
  • 相关文献

参考文献5

二级参考文献44

  • 1程艳玲,仇士东.左旋氨氯地平的临床药理及临床应用[J].齐鲁药事,2006,25(10):612-614. 被引量:9
  • 2Zhao D, Liu J, Wang W, et, al. Epidemiological transition of stroke in China: twenty - one - year observational study from the Sino - MONICA -Beijing Project[J]. Stroke, 2008,39(6) :1668 -1674.
  • 3Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta - analysis [J]. BMJ, 2002,325 (7374) :1202.
  • 4Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke prevention: a meta - analysis [J]. Lancet, 2007, 369 (9576) :1876 -1882.
  • 5Rosa EM, Kramer C. Castrol association between coronary artery atherosclerosis and the intima - media thickness of the common carotid artery measured on ultrasonography [J]. Arq Bra Cardiol, 2003,80 ( 6) : 589 -592.
  • 6Haim M, Tanne D, Goldbourt U, et al. Serum homocysteine and long - term risk of myocardial infarction and sudden death in patients with coronaryheart disease [J]. Cardiology, 2007,107 (1) :52 - 56.
  • 7Biswas A, Ranjan R, Meena A, et, al. Homocystine levels, polymorphisms and the risk of ischemic stroke in young Asian Indians [J]. J Stroke Cerebrovasc Dis, 2009, 18 ( 20) : 103 - 11 o.
  • 8Tseng YL, Chang YY, Liu JS, et, al. Association of plasma homocysteine concentration with cerebral white matter hyperintensity on magnetic resonance in stroke patients [J]. J Neurol Sci, 2009,284 ( 112) : 36 - 39.
  • 9Zanchetti A. Bond MG. Hennig M. et al. European Lacidipine Study on Atherosclerosis investigators. Calcium antagonist lacidipine slows down progression of asympomatic carotid atheroselerosis. Principal results of the European lacidipine study on Atherosclerosis ( ELSA). a randomized doubleblind , long - term trial [J]. Circulation. 2002. 106 (19) :2422 -2427.
  • 10Maruthur NM, Wang NY, Appel LJ. Lifestyle interventions reduce coronary heart disease risk: results from the PREMIER Trial, Circulation,2009,118(15) :2026-2031.

共引文献118

同被引文献20

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部